論文種別 | 症例報告 |
言語種別 | 英語 |
査読の有無 | その他(不明) |
表題 | Antitumor Necrosis Factor-Refractory Esophageal Lesions in Crohn's Disease Successfully Treated With Upadacitinib. |
掲載誌名 | 正式名:ACG case reports journal 略 称:ACG Case Rep J ISSNコード:23263253/23263253 |
掲載区分 | 国外 |
巻・号・頁 | 12(5),pp.e01713 |
著者・共著者 | Naohiro Nakamura, Yusuke Honzawa, Yuka Ito, Yasuki Sano, Naoto Yagi, Eiko Saito, Norimasa Fukata, Makoto Naganuma |
発行年月 | 2025/05 |
概要 | A 39-year-old man with a 5-year history of ileocolonic Crohn's disease received treatment with 6-mercaptopurine and adalimumab. A computed tomography scan was performed due to a persistent cough, revealing esophageal wall thickening. Esophagogastroduodenoscopy identified multiple longitudinal ulcers throughout the esophagus. Despite infliximab treatment, the esophageal lesions deteriorated, leading to the initiation of upadacitinib for antitumor necrosis factor-refractory esophageal lesions. Consequently, all esophageal lesions were healed, and serum biomarkers returned negative results. Although upadacitinib is effective for patients with ileocolonic Crohn's disease, this is the first case demonstrating its efficacy for refractory esophageal lesions. |
DOI | 10.14309/crj.0000000000001713 |
PMID | 40386539 |